Physician profile
David Wesley Carpenter
NPI 1164573192
$6,008.74
in general payments reported to CMS, 2019-2025
44 companies · $1,209 in 2025
The $1,209 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $255 · 2021: $675 · 2022: $647 · 2023: $1,371 · 2024: $1,523 · 2025: $1,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,101.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,043.70 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $652.36 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $578.35 | 2019-2025 | |
| Abbvie INC. | $550.84 | 2021-2025 | Vraylar, Ubrelvy |
| Astellas Pharma US INC | $407.57 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $371.13 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $228.46 | 2022-2023 | Quviviq |
| Abbott Laboratories | $225.09 | 2022-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $209.50 | 2019-2025 | Mounjaro, Zepbound |
| Radius Health, INC. | $185.15 | 2023-2025 | |
| Amgen INC. | $182.35 | 2019-2025 | Evenity, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $176.78 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.98 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $151.17 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $111.52 | 2021-2023 | Verquvo, Belsomra |
Show all 40 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.